H.C. Wainwright & Co. reaffirmed its Buy rating and $15.00 price target for Emergent BioSolutions stock (NYSE:EBS). The ...
Shionogi will receive $375 million to develop a long-acting protease inhibitor designed to prevent SARS-CoV-2 infection in ...
Clinical-stage Australian biotechnology company Vaxxas will receive $3.2 million from the US Biomedical Advanced Research and ...
today announced the company won the Biomedical Advanced Research and Development Authority (BARDA) Patch Forward competition and presented at an event during the J.P. Morgan Healthcare Conference ...
Vaxxas, a clinical-stage biotechnology company commercializing a novel high-density microarray patch (HD-MAP) vaccination platform, has been named a C ...
Emergent BioSolutions (EBS) announced that the Biomedical Advanced Research and Development Authority executed a contract modification for the ...
Moderna, Inc. (NASDAQ:MRNA) today announced ongoing support from the U.S. Department of Health and Human Services (HHS) to accelerate the development of mRNA-based pandemic influenza vaccines. The ...
today announced the company won the Biomedical Advanced Research and Development Authority (BARDA) Patch Forward competition and presented at an event during the J.P. Morgan Healthcare Conference ...